Poteligeo

Chemical Namemogamulizumab-kpkc
Dosage FormInjection (intravenous; 20 mg/5 mL (4 mg/mL))
Drug ClassMonoclonal antibodies
SystemSkin
CompanyKyowa Kirin Inc.
Approval Year2018

Indication

  • To treat relapsed or refractory myocosis fungoides or S├ęzary syndrome in adults who have had at least one prior systemic therapy.
Last updated on 10/15/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Poteligeo (Mogamulizumab-kpkc) Prescribing Information 2018Kyowa Kirin, Inc., Bedminster, NJ